All In MedTech

FDA programs

The FDA Breakthrough Devices Program: criteria, benefits and the full list

Breakthrough device designation explained: FDA Breakthrough Devices Program criteria under section 515B, how to request it, and what it offers.

By the All In MedTech editorial team · Published November 19, 2026 · 6 min read

The FDA Breakthrough Devices Program gives priority treatment to medical devices that may offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. A designated device gets more frequent, more senior interaction with FDA during development and prioritized review of its submissions. It does not lower the bar for marketing: the device still needs a 510(k) clearance, a De Novo grant or a PMA approval.

This post covers the legal criteria, how a sponsor asks for designation, what the program actually provides, and where to see the designated devices that have reached the market.

Where the program comes from

The program is written into law at section 515B of the Federal Food, Drug, and Cosmetic Act, which was added by section 3051 of the 21st Century Cures Act in 2016 and later amended. FDA explains how it runs the program in its guidance Breakthrough Devices Program. The first final version of that guidance was issued in December 2018, and an updated final guidance was announced in the Federal Register in September 2023.

The program replaced FDA's earlier Expedited Access Pathway. Devices designated under that pathway are treated as part of the Breakthrough Devices Program, which is why FDA's counts include them.

FDA's program page is Breakthrough Devices Program. Guidance can be revised, so check that page for the current version before relying on any detail.

The eligibility criteria

A device can be considered only if it will go through one of the three premarket pathways: a PMA, a 510(k) or a De Novo request. It then has to meet two criteria.

First criterion. The device provides more effective treatment or diagnosis of a life-threatening or irreversibly debilitating human disease or condition.

Second criterion. The device meets at least one of these four conditions:

OptionWhat it means in practice
Represents breakthrough technologyThe technology itself is new, not just an incremental change to existing devices.
No approved or cleared alternatives existNothing on the market addresses the same use.
Offers significant advantages over existing approved or cleared alternativesFor example, better outcomes, fewer complications, or a benefit for patients who cannot use current options.
Device availability is in the best interest of patientsA broader catch-all that FDA assesses case by case.

A few points are worth knowing about how FDA reads these.

  • "More effective" is judged on the totality of information about the device, including its potential to make a clinically meaningful difference and its benefits and risks compared with standard of care. A sponsor does not need to have proven this already. Designation is a forward-looking judgment made during development.
  • The 2023 update to the guidance says the program can apply to certain devices that benefit populations affected by health or healthcare disparities, and that improved accessibility can count toward the first criterion.
  • Under the SUPPORT Act, certain non-addictive medical products to treat pain or addiction can also qualify.

If a device fails the first criterion because the condition is not life-threatening or irreversibly debilitating, FDA points sponsors to a sister program, the Safer Technologies Program (STeP), which is aimed at devices that make existing treatments or diagnostics safer.

How to request designation

A sponsor asks for designation through a Q-Submission titled "Designation Request for Breakthrough Device." FDA asks that this request be the only item in that Q-Submission. It can be filed through the CDRH Customer Collaboration Portal.

The request can be made at any point before the marketing submission is sent. Because most of the program's features apply during development, an earlier request leaves more time to use them. A request typically covers:

  1. A description of the device and how it works.
  2. The proposed indication for use.
  3. The device's regulatory history, such as any earlier Q-Submissions or IDEs.
  4. An explanation of how the device meets each criterion, with supporting data.
  5. The planned marketing submission type: 510(k), De Novo or PMA.

On timing, FDA says it intends to ask for any additional information within 30 days of receiving a request and that sponsors can expect a decision letter within 60 calendar days of receipt. Slow or incomplete answers to FDA's questions can lead to a denial.

What designation gives you

The benefits are about access and priority, not a different legal standard. Section 515B and the guidance describe several features:

  • Interactive communication. Sponsors can use program options such as sprint discussions on a specific topic, data development plan discussions, and clinical protocol agreement requests.
  • Senior involvement. FDA commits to involving senior management and experienced review staff, with a review team that supports the device through development.
  • Prioritized review. Later Q-Submissions, IDE applications and the marketing submission itself are reviewed with priority.
  • Flexible study design. The statute directs FDA toward efficient and flexible clinical study designs and, where scientifically appropriate, accepting some data collection after marketing rather than before it. This applies within the usual evidence standards and depends on the device.

Designation can also matter outside FDA. CMS has created payment and coverage pathways that refer to Breakthrough status, including an alternative route for the new technology add-on payment and the Transitional Coverage for Emerging Technologies pathway. These are CMS programs with their own rules. See NTAP explained and TCET explained for how they work.

What designation does not do

It is easy to read too much into the word "breakthrough." In particular:

  • It is not a marketing authorization. A designated device is still investigational until it is cleared, granted or approved. Many designated devices have not reached the market.
  • It does not change the review standard. A 510(k) still needs substantial equivalence, a De Novo still needs reasonable assurance of safety and effectiveness with appropriate controls, and a PMA still needs reasonable assurance of safety and effectiveness.
  • It does not guarantee speed. Prioritized review moves the submission up the queue, but development time is driven by the evidence the device needs.
  • It does not guarantee payment. Medicare and private payers make separate decisions.

How many devices have been designated

FDA publishes running totals on its program page. As of June 30, 2026, FDA reported 1,320 Breakthrough designations granted (1,299 by CDRH and 21 by CBER) and 210 marketing authorizations for designated devices (205 CDRH and 5 CBER). These totals include devices designated under the Expedited Access Pathway. FDA updates the figures periodically, so check the program page for the latest count.

The gap between the two numbers reflects that designation comes early. Some designated devices are still in development, some were abandoned, and some will reach the market later.

FDA's public list covers designated devices that have received marketing authorization. Designations for devices still in development are not on it. Companies often announce their own designations, but those announcements are not an FDA record, so a press release is the only public trace of many designations.

Finding Breakthrough devices that reached the market

This site loads FDA's list of Breakthrough devices with marketing authorization from the program page. The copy used here is dated June 30, 2026 and has 206 entries, and each entry links to the FDA decision behind it.

Because the program spans all three pathways, the list mixes 510(k) clearances, De Novo grants and PMA approvals. A Breakthrough device that is the first of its kind often goes through De Novo, while higher-risk implants and life-sustaining devices usually go through PMA. For how those pathways differ, read 510(k) vs De Novo vs PMA.

Most designated devices need clinical data before authorization, which usually means a clinical study run under an investigational device exemption. You can look for those studies on the device trials page, and the IDE guide explains how those studies are regulated.

Summary

The Breakthrough Devices Program is a development and review priority program set out in section 515B. To qualify, a device must offer more effective treatment or diagnosis of a life-threatening or irreversibly debilitating condition and meet at least one of four further conditions. A sponsor asks through a Q-Submission and gets a decision within about 60 days. Designation brings closer FDA interaction and prioritized review, but the device still has to meet the normal standard for its pathway before it can be sold.

Frequently asked questions

What is a Breakthrough Device designation?
It is a status FDA grants to certain devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, giving the sponsor more interaction with FDA and prioritized review.
Does Breakthrough designation mean a device is approved?
No. Designation is granted during development, and the device still has to be cleared, granted or approved through a 510(k), De Novo or PMA under the usual legal standards.
How long does FDA take to decide on a Breakthrough request?
FDA says sponsors can expect a decision letter within 60 calendar days of FDA receiving the request, and it intends to ask for any missing information within 30 days.
How many devices have Breakthrough designation?
FDA reports 1,320 designations granted and 210 marketing authorizations as of June 30, 2026, counting devices first designated under the earlier Expedited Access Pathway.

For information only, not medical, legal or investment advice. Facts about FDA, CMS and SEC rules are current as of the publication date; check the linked official source for changes.

Keep reading